In animal models with nonalcoholic steatohepatitis (NASH), the administration of FGF21 analogues was associated with reduced expression of several proinflammatory cytokines, including tumor necrosis factor a (TNF-a), interleukin-6 (IL-6), IL-1, and interferon-γ (IFN-γ) [44]. Here, IL6 is linked to metabolic dysfunction-associated steatohepatitis.